Abstract: Cytology triage has been generally recommended for human papillomavirus (HPV)-positive women, but is highly dependent on well-trained cytologists. The present study was designed to explore whether HPV E6/E7 mRNA detection in cervical exfoliated cells can be a potential triage for HPV-positive women from a clinic-based population. Both the primary HPV testing and Papanicolaou (Pap) test were performed on all eligible HPV-positive women. HPV E6/E7 mRNA was detected by QuantiVirus^® HPV E6/E7 mRNA assay in cervical exfoliated cells. All HPV-positive women underwent colposcopy and further biopsy if indicated. The data were assessed by Pearson’s Chi-squared test and the receiver operating characteristic curve. A total of 404 eligible HPV-positive women were enrolled. Positive rate of E6/E7 mRNA in high-grade squamous intraepithelial lesion (HSIL) cases was higher than that in low-grade squamous intraepithelial lesion (LSIL) or normal cases. There was no statistical difference found between mRNA and cytological testing with sensitivity (89.52% vs. 86.67%, P=0.671), specificity (48.96% vs. 48.96%, P=1.000), positive predictive value (39.00% vs. 38.24%, P=1.000), and negative predictive value (92.76% vs. 90.97%, P=0.678) for detecting ≥HSIL. HPV E6/E7 mRNA detection in cervical exfoliated cells shows the same performance as Pap triage for HSIL identification for HPV-positive women. Detection of HPV E6/E7 mRNA may be used as a new triage option for HPV-positive women.

宫颈脱落细胞人乳头瘤病毒（HPV）E6/E7 mRNA检测在HPV阳性女性筛查中的应用

[1]Arbyn, M., Ronco, G., Anttila, A., et al., 2012. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 30(5):F88-F99.

[2]Benevolo, M., Vocaturo, A., Caraceni, D., et al., 2011. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J. Clin. Microbiol., 49(7):2643-2650.

[3]Castle, P.E., Dockter, J., Giachetti, C., et al., 2007. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin. Cancer Res., 13(9):2599-2605.

[4]Chellappan, S., Kraus, V.B., Kroger, B., et al., 1992. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. PNAS, 89(10):4549-4553.

[5]Clifford, G.M., Smith, J.S., Aguado, T., et al., 2003. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer, 89(1):101-105.

[6]Condel, J.L., Mahood, L.K., Grzybicki, D.M., et al., 2002. Papanicolaou tests diagnosed as atypical by a cytotechnologist and downgraded to benign by a pathologist: a measure of laboratory quality. Am. J. Clin. Pathol., 117(4):534-540.

[7]Coquillard, G., Palao, B., Patterson, B.K., 2011. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol. Oncol., 120(1):89-93.

[8]Cuschieri, K., Wentzensen, N., 2008. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev., 17(10):2536-2545.

[9]de Sanjose, S., Diaz, M., Castellsague, X., et al., 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis., 7(7):453-459.

[10]Discacciati, M.G., Da, S.I., Villa, L.L., et al., 2014. Prognostic value of DNA and mRNA E6/E7 of human papillomavirus in the evolution of cervical intraepithelial neoplasia grade 2. Biomark Insights, 9:15-22.

[11]Franceschi, S., Denny, L., Irwin, K.L., et al., 2011. Eurogin 2010 roadmap on cervical cancer prevention. Int. J. Cancer, 128(12):2765-2774.

[12]Giorgi Rossi, P., Benevolo, M., Vocaturo, A., et al., 2013. Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study. PLoS ONE, 8(2):e57600.

[13]Ho, C.M., Lee, B.H., Chang, S.F., et al., 2010. Type-specific human papillomavirus oncogene messenger RNA levels correlate with the severity of cervical neoplasia. Int. J. Cancer, 127(3):622-632.

[14]Jeantet, D., Schwarzmann, F., Tromp, J., et al., 2009. NucliSENS EasyQ HPV v1 test—testing for oncogenic activity of human papillomaviruses. J. Clin. Virol., 45(1):S29-S37.

[15]Kitchener, H.C., Almonte, M., Thomson, C., et al., 2009. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol., 10(7):672-682.

[16]Liu, T.Y., Xie, R., Luo, L., et al., 2014. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples. J. Virol. Methods, 196:120-125.

[17]Mayrand, M.H., Duarte-Franco, E., Rodrigues, I., et al., 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med., 357(16):1579-1588.

[18]Moyer, V.A., 2012. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med., 156(12):880-891.

[19]Naucler, P., Ryd, W., Tornberg, S., et al., 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med., 357(16):1589-1597.

[20]Pierry, D., Weiss, G., Lack, B., et al., 2012. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than Papanicolaou screening for women regardless of age. Arch. Pathol. Lab. Med., 136(8):956-960.

[21]Ronco, G., Giorgi-Rossi, P., Carozzi, F., et al., 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol., 11(3):249-257.

[22]Scheffner, M., Werness, B.A., Huibregtse, J.M., et al., 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63(6):1129-1136.

[23]Scheurer, M.E., Tortolero-Luna, G., Adler-Storthz, K., 2005. Human papillomavirus infection: biology, epidemiology, and prevention. Int. J. Gynecol. Cancer, 15(5):727-746.

[24]Schiffman, M., Wentzensen, N., Wacholder, S., et al., 2011. Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst., 103(5):368-383.

[25]Siebers, A.G., Klinkhamer, P.J., Grefte, J.M., et al., 2009. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA, 302(16):1757-1764.

[26]Sorbye, S.W., Arbyn, M., Fismen, S., et al., 2011. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS ONE, 6(10):e26022.

[27]Sotlar, K., Stubner, A., Diemer, D., et al., 2004. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J. Med. Virol., 74(1):107-116.

[28]Tavassoéli, F.A., Devilee, P., 2003. Pathology and Genetics Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, France.

[29]Torre, L.A., Bray, F., Siegel, R.L., et al., 2015. Global cancer statistics, 2012. CA Cancer J. Clin., 65(2):87-108.

[30]Walboomers, J.M., Jacobs, M.V., Manos, M.M., et al., 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189(1):12-19.

[31]Wright, T.J., Schiffman, M., 2003. Adding a test for human papillomavirus DNA to cervical-cancer screening. N. Engl. J. Med., 348(6):489-490.

[32]Zappacosta, R., Caraceni, D., Ciccocioppo, L., et al., 2013. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme. Gynecol. Oncol., 128(3):427-432.